乙基{2-[4-(三氟甲基)苯基]-1,3-噻唑-4-基}乙酸酯 | 680215-92-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乙基{2-[4-(三氟甲基)苯基]-1,3-噻唑-4-基}乙酸酯
• 中文别名: 2-[4-(三氟甲基)苯]噻唑-4-乙酸乙酯
• 英文名称: [2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethanoic acid ethyl ester
• 英文别名: [2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-acetic acid ethyl ester；Ethyl 2-{2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl}acetate；ethyl 2-[2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl]acetate
• CAS: 680215-92-3
• 化学式: C₁₄H₁₂F₃NO₂S
• 分子量: 315.316
• InChiKey: MZVGKOLXAQXCPL-UHFFFAOYSA-N

物化性质

• 熔点：
  37.8-40.6°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934100090

反应信息

• 作为产物：
  描述：

  Ethyl 3-ethoxy-4-bromo-2-butenoate 、 4-(三氟甲基)硫代苯甲酰胺 在 六氟异丙醇 、 sodium acetate 作用下， 反应 8.0h， 以99%的产率得到乙基{2-[4-(三氟甲基)苯基]-1,3-噻唑-4-基}乙酸酯
  参考文献：
  名称：

  通过使用级联方案模块化合成噻唑啉和噻唑衍生物。

  摘要：

  噻唑啉和噻唑是许多天然产物，许多药物和许多有用的分子（例如用于金属催化的配体）的组成部分。我们报告了噻唑和噻唑啉合成的第一个通用的合成方案。通过使用容易获得且便宜的底物，可以有效地合成新型分子。反应条件温和，无需后处理和柱纯化即可得到纯净产物。

  DOI：

  10.1039/c7ra05993k

文献信息

• Substituted heteroaryl- and phenylsulfamoyl compounds
  申请人：Hamanaka S. Ernest

  公开号：US20050288340A1

  公开（公告）日：2005-12-29

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，包含这些化合物的制药组合物和将这些化合物用作过氧化物酶增殖剂受体（PPAR）激动剂。PPARα激动剂，包含这些化合物的制药组合物，以及将这些化合物用于提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，因此治疗由低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加重的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Substituted Heteroaryl- and Phenylsulfamoyl Compounds
  申请人：Hamanaka S. Ernest

  公开号：US20060229363A1

  公开（公告）日：2006-10-12

  The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物、含有该类化合物的药物组合物及其作为过氧化物酶体增殖物激活受体（PPAR）激动剂的用途。该化合物可以作为PPARα激动剂，含有该类化合物的药物组合物可用于提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加剧的疾病，如动脉硬化和心血管疾病，在哺乳动物，包括人类中使用。该化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS
  申请人：HAMANAKA S. ERNEST

  公开号：US20080090829A1

  公开（公告）日：2008-04-17

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，含有这种化合物的药物组合物以及将这种化合物用作过氧化物酶体增殖物激活受体（PPAR）激动剂。PPARα激动剂，含有这种化合物的药物组合物以及使用这种化合物升高某些血浆脂质水平，包括高密度脂蛋白胆固醇并降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并因此治疗低密度脂蛋白胆固醇和/或高甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Modular synthesis of thiazoline and thiazole derivatives by using a cascade protocol
  作者：Zakeyah A. Alsharif、Mohammad A. Alam

  DOI：10.1039/c7ra05993k

  日期：——

  natural products, a number of drugs, and many useful molecules such as ligands for metal catalysis. We report the first common synthetic protocol for the synthesis of thiazoles and thiazolines. Novel molecules are efficiently synthesized by using readily available and inexpensive substrates. The reaction conditions are mild and pure products are obtained without work-up and column purification.

  噻唑啉和噻唑是许多天然产物，许多药物和许多有用的分子（例如用于金属催化的配体）的组成部分。我们报告了噻唑和噻唑啉合成的第一个通用的合成方案。通过使用容易获得且便宜的底物，可以有效地合成新型分子。反应条件温和，无需后处理和柱纯化即可得到纯净产物。